Analytical Development

Development of novel, potentially groundbreaking manufacturing equipment and consumables for cell therapies is a complicated dance. It is a delicate balance of conflicting development and commercial priorities against customer requirements and the need to get to market quickly. In this case a client came to DHC concerned with the progress of their internal development program and worried about the maturity of their integrated bioreactor system for the manufacture of CAR-T and next generation cell therapies.

Development of a CAR-T cell therapy licensed from an academic institution required support in developing a pre-IND and IND-enabling nonclinical strategy.

An emergent situation calls for simultaneous problem-solving on multiple fronts.
This client approached DHC for interim leadership support as they faced a critical clinical supply shortage—driven by manufacturing and comparability challenges—for their clinical stage lipid nanoparticle (LNP)-based drug product.

Our clients may experience a variety of situations that lead to a leadership gap within their organizations. Senior staff at Dark Horse possess years of leadership experience and can help fill the gap and keep operations moving forward. With senior staff available for nearly any technical or strategic need (and the ability for each of them to call upon 40+ technical SMEs for additional support), this has become a common request for DHC.

Requests for a roadmap to IND are common queries at DHC. This case study combines the experiences of a range of client projects to extrapolate the elements of a typical roadmap. In this type of engagement, DHC’s cross-functional expertise provides clients with an integrated understanding of the major activities, timelines, costs and value inflection points on the path to IND. Project deliverables are valuable both for internal planning and for fundraising activities.

A pure-play gene therapy client whose product was just being spun out of academia brought DHC in early to provide long-term guidance, conceptualizing and building a dev process that would stand up to the challenges of future trial phases and into commercial production.

This case study follows the experience of a client who is new to CGT (though otherwise practiced in late stage processes) and requires CRL remediation to prepare for BLA resubmission.

Combine BLA rejections and late-stage product delays with the rising proof of comparability burden as therapies approach a regulatory hurdle, and an expert comparability review becomes a near-necessity.

Nonsensical, counterintuitive, or otherwise "off" data is likely to signal a problem. A team with remediation experience, like Dark Horse's, can perform a failure analysis to identify and remediate the source(s) of the issue. 

Dark Horse offers varying levels of analytical support, ranging from high-level strategic oversight to detailed tactical operational support. In this case, the client required a broad scope of guidance while preparing to file for licensure.

Assistance with the design/use of studies demonstrating biological relevance of a lead candidate in vitro potency assay demonstrates analytical and non/preclinical core compentencies.